



BMI CHART

Date: 24/9/

Name: _____ Age: _____ yrs

Sex: M / F

BP: 150/80 mm/Hg Height (cms): 158 cm Weight(kgs): 71.5 Kg BMI: _____

WEIGHT lbs 100 105 110 115 120 125 130 135 140 145 150 155 160 165 170 175 180 185 190 195 200 205 210 215
kgs 45.5 47.7 50.0 52.3 54.5 56.8 59.1 61.4 63.6 65.9 68.2 70.5 72.7 75.0 77.3 79.5 81.8 84.1 86.4 88.6 90.9 93.2 95.5 97.7

HEIGHT in/cm	Underweight				Healthy				Overweight				Obese				Extremely Obese							
5'0" - 152.4	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42
5'1" - 154.9	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	
5'2" - 157.4	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39		
5'3" - 160.0	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38		
5'4" - 162.5	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37			
5'5" - 165.1	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37		
5'6" - 167.6	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37		
5'7" - 170.1	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36		
5'8" - 172.7	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36		
5'9" - 176.2	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35		
5'10" - 177.8	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35		
5'11" - 180.3	14	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34		
6'0" - 182.8	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34		
6'1" - 185.4	13	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33		
6'2" - 187.9	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33		
6'3" - 190.5	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33		
6'4" - 193.0	12	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32		

Doctors Notes:

Signature

Hiranandani Healthcare Pvt. Ltd.
 Mini Sea Shore Road, Sector 10 -A, Vashi, Navi Mumbai - 400703
 Board Line: 022 - 39199222 | Fax: 022 - 39199220
 Emergency: 022 - 39199100 | Ambulance: 1255
 For Appointment: 022 - 39199222 | Health Checkup: 022 - 39199300
 www.fortishealthcare.com |
 CIN : U85100MH2005PTC154823
 GST IN: 27AABCH5894D1ZG | PAN NO: AABCH5894D



Hiranandani
HOSPITAL
 (A Fortis Network Hospital)

UHID	4609607	Date	24/09/2022		
Name	Mrs.Mangal Chandrakant Patil	Sex	Female	Age	41
OPD	Pap Smear	Health Check-up			

Allyls / P212

LMP: 14.9.22

PMC: 3/30d, RMP

Drug allergy:
 Sys illness:

Psp - exp (HP) pap

- Breast exam @

- SBE explained

Adv
 - Fuc reports

reho

Hiranandani Healthcare Pvt. Ltd.
 Mini Sea Shore Road, Sector 10 -A, Vashi, Navi Mumbai - 400703
 Board Line: 022 - 39199222 | Fax: 022 - 39199220
 Emergency: 022 - 39199100 | Ambulance: 1255
 For Appointment: 022 - 39199222 | Health Checkup: 022 - 39199300
 www.fortishealthcare.com |
 CIN : U85100MH2005PTC154823
 GST IN: 27AABCH5894D1ZG | PAN NO: AABCH5894D



Hiranandani
 HOSPITAL

(A Fortis Network Hospital)

UHID	4609607	Date	24/09/2022		
Name	Mrs. Mangal Chandrakant Patil	Sex	Female	Age	41
OPD	Ophthal 14	Health Check-up			

Drug allergy:
 Sys illness:

Ref → R.G. Pluse Glc.
 Ref → L.G. Pluse Glc.
 Add + 1.00 → W.C
 Add + 1.00 → W.O

Autseg (oral)
 IOP → 14.5
 IOP → 15.2

myopia
 Conclis

Ref



UHID	4609607	Date	24/09/2022		
Name	Mrs. Mangal Chandrakant Patil	Sex	Female	Age	41
OPD	Dental 12	Health Check-up			

Drug allergy:
 Sys illness:

Caries $\frac{762}{7} \mid \frac{67}{347}$

missing $\frac{6}{6}$

Stainy + +

calculus + +

Treatment:

Adv. filling $\frac{762}{7} \mid \frac{67}{347}$

Adv. replacement + + + +

Adv. Oral prophylaxis


PATIENT NAME : MRS. MANGAL CHANDRAKANT PATIL

PATIENT ID : **FH.4609607** CLIENT PATIENT ID :
 ACCESSION NO : **0022VI005164** AGE : 41 Years SEX : Female DATE OF BIRTH : 01/08/1981
 DRAWN : 24/09/2022 12:50 RECEIVED : 24/09/2022 12:55 REPORTED : 24/09/2022 15:15
 CLIENT NAME : **FORTIS VASHI-CHC -SPLZD** REFERRING DOCTOR : SELF

Test Report Status	Results	Biological Reference Interval	Units
Final			

KIDNEY PANEL - 1

SERUM BLOOD UREA NITROGEN 7 6 - 20 mg/dL
 BLOOD UREA NITROGEN
 METHOD : UREASE - UV




CREATININE EGFR- EPI 0.73 0.60 - 1.10 mg/dL
 CREATININE
 METHOD : ALKALINE PICRATE KINETIC JAFFES
 AGE 41 years
 GLOMERULAR FILTRATION RATE (FEMALE) 105.89 Refer Interpretation Below mL/min/1.73m
 METHOD : CALCULATED PARAMETER



PATIENT NAME : MRS. MANGAL CHANDRAKANT PATIL

PATIENT ID : **FH.4609607** CLIENT PATIENT ID :
 ACCESSION NO : **0022VI005164** AGE : 41 Years SEX : Female DATE OF BIRTH : 01/08/1981
 DRAWN : 24/09/2022 12:50 RECEIVED : 24/09/2022 12:55 REPORTED : 24/09/2022 15:15
 CLIENT NAME : **FORTIS VASHI-CHC -SPLZD** REFERRING DOCTOR : SELF

Test Report Status	Results	Biological Reference Interval	Units
Final			



BUN/CREAT RATIO	9.59	5.00 - 15.00	
BUN/CREAT RATIO			
METHOD : CALCULATED PARAMETER			
URIC ACID, SERUM			mg/dL
URIC ACID	3.4	2.6 - 6.0	
METHOD : URICASE UV			
TOTAL PROTEIN, SERUM			g/dL
TOTAL PROTEIN	8.2	6.4 - 8.2	
METHOD : BIURET			
ALBUMIN, SERUM			g/dL
ALBUMIN	3.8	3.4 - 5.0	
METHOD : BCP DYE BINDING			
GLOBULIN	4.4	High 2.0 - 4.1	g/dL
GLOBULIN			
METHOD : CALCULATED PARAMETER			
ELECTROLYTES (NA/K/CL), SERUM			mmol/L
SODIUM	140	136 - 145	
METHOD : ISE INDIRECT			
POTASSIUM	4.44	3.50 - 5.10	mmol/L
METHOD : ISE INDIRECT			
CHLORIDE	105	98 - 107	mmol/L
METHOD : ISE INDIRECT			
PHYSICAL EXAMINATION, URINE			
COLOR	PALE YELLOW		

SRL Ltd
 HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD,
 SECTOR 10,
 NAVI MUMBAI, 400703
 MAHARASHTRA, INDIA
 Tel : 022-39199222,022-49723322, Fax :
 CIN - U74899PB1995PLC045956
 Email : -



Scan to View Details



Scan to View Report

PATIENT NAME : MRS. MANGAL CHANDRAKANT PATIL

PATIENT ID : **FH.4609607** CLIENT PATIENT ID :
 ACCESSION NO : **0022VI005164** AGE : 41 Years SEX : Female DATE OF BIRTH : 01/08/1981
 DRAWN : 24/09/2022 12:50 RECEIVED : 24/09/2022 12:55 REPORTED : 24/09/2022 15:15
 CLIENT NAME : **FORTIS VASHI-CHC -SPLZD** REFERRING DOCTOR : SELF

Test Report Status	Results	Biological Reference Interval	Units
--------------------	---------	-------------------------------	-------

METHOD : PHYSICAL
 APPEARANCE CLEAR
 METHOD : VISUAL
 SPECIFIC GRAVITY <=1.005 1.003 - 1.035
 METHOD : REFLECTANCE SPECTROPHOTOMETRY (APPARENT PKA CHANGE OF PRETREATED POLYELECTROLYTES IN RELATION TO IONIC CONCENTRATION)

CHEMICAL EXAMINATION, URINE

PH 6.0 4.7 - 7.5
 METHOD : REFLECTANCE SPECTROPHOTOMETRY- DOUBLE INDICATOR METHOD
 PROTEIN NOT DETECTED NOT DETECTED
 METHOD : REFLECTANCE SPECTROPHOTOMETRY - PROTEIN-ERROR-OF-INDICATOR PRINCIPLE
 GLUCOSE NOT DETECTED NOT DETECTED
 METHOD : REFLECTANCE SPECTROPHOTOMETRY, DOUBLE SEQUENTIAL ENZYME REACTION-GOD/POD
 KETONES NOT DETECTED NOT DETECTED
 METHOD : REFLECTANCE SPECTROPHOTOMETRY, ROTHERA'S PRINCIPLE
 BLOOD NOT DETECTED NOT DETECTED
 METHOD : REFLECTANCE SPECTROPHOTOMETRY, PEROXIDASE LIKE ACTIVITY OF HAEMOGLOBIN
 BILIRUBIN NOT DETECTED NOT DETECTED
 METHOD : REFLECTANCE SPECTROPHOTOMETRY, DIAZOTIZATION- COUPLING OF BILIRUBIN WITH DIAZOTIZED SALT
 UROBILINOGEN NORMAL NORMAL
 METHOD : REFLECTANCE SPECTROPHOTOMETRY (MODIFIED EHRlich REACTION)
 NITRITE NOT DETECTED NOT DETECTED
 METHOD : REFLECTANCE SPECTROPHOTOMETRY, CONVERSION OF NITRATE TO NITRITE
 LEUKOCYTE ESTERASE NOT DETECTED NOT DETECTED
 METHOD : REFLECTANCE SPECTROPHOTOMETRY, ESTERASE HYDROLYSIS ACTIVITY

MICROSCOPIC EXAMINATION, URINE

PUS CELL (WBC'S) 2-3 0-5 /HPF
 METHOD : MICROSCOPIC EXAMINATION
 EPITHELIAL CELLS 0-1 0-5 /HPF
 METHOD : MICROSCOPIC EXAMINATION
 ERYTHROCYTES (RBC'S) NOT DETECTED NOT DETECTED /HPF
 METHOD : MICROSCOPIC EXAMINATION
 CASTS NOT DETECTED
 METHOD : MICROSCOPIC EXAMINATION
 CRYSTALS NOT DETECTED NOT DETECTED
 METHOD : MICROSCOPIC EXAMINATION
 BACTERIA NOT DETECTED NOT DETECTED
 METHOD : MICROSCOPIC EXAMINATION
 YEAST NOT DETECTED NOT DETECTED
 METHOD : MICROSCOPIC EXAMINATION
 REMARKS URINARY MICROSCOPIC EXAMINATION DONE ON URINARY CENTRIFUGED SEDIMENT.



Scan to View Details



Scan to View Report



PATIENT NAME : MRS. MANGAL CHANDRAKANT PATIL

PATIENT ID : **FH.4609607** CLIENT PATIENT ID :
 ACCESSION NO : **0022VI005164** AGE : 41 Years SEX : Female DATE OF BIRTH : 01/08/1981
 DRAWN : 24/09/2022 12:50 RECEIVED : 24/09/2022 12:55 REPORTED : 24/09/2022 15:15
 CLIENT NAME : **FORTIS VASHI-CHC -SPLZD** REFERRING DOCTOR : SELF

Test Report Status	Results	Biological Reference Interval
Final		

Interpretation(s)

SERUM BLOOD UREA NITROGEN-

Causes of Increased levels

- Pre renal
 - High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal
- Renal Failure
- Post Renal
 - Malignancy, Nephrolithiasis, Prostatism

Causes of decreased levels

- Liver disease
- SIADH.

CREATININE EGFR- EPI-

GFR— Glomerular filtration rate (GFR) is a measure of the function of the kidneys. The GFR is a calculation based on a serum creatinine test. Creatinine is a muscle waste product that is filtered from the blood by the kidneys and excreted into urine at a relatively steady rate. When kidney function decreases, less creatinine is excreted and concentrations increase in the blood. With the creatinine test, a reasonable estimate of the actual GFR can be determined.

A GFR of 60 or higher is in the normal range.
 A GFR below 60 may mean kidney disease.
 A GFR of 15 or lower may mean kidney failure.

Estimated GFR (eGFR) is the preferred method for identifying people with chronic kidney disease (CKD). In adults, eGFR calculated using the Modification of Diet in Renal Disease (MDRD) Study equation provides a more clinically useful measure of kidney function than serum creatinine alone.

The CKD-EPI creatinine equation is based on the same four variables as the MDRD Study equation, but uses a 2-slope spline to model the relationship between estimated GFR and serum creatinine, and a different relationship for age, sex and race. The equation was reported to perform better and with less bias than the MDRD Study equation, especially in patients with higher GFR. This results in reduced misclassification of CKD.

The CKD-EPI creatinine equation has not been validated in children & will only be reported for patients = 18 years of age. For pediatric and childrens, Schwartz Pediatric Bedside eGFR (2009) formulae is used. This revised "bedside" pediatric eGFR requires only serum creatinine and height.

URIC ACID, SERUM-

Causes of Increased levels

- Dietary
 - High Protein Intake.
 - Prolonged Fasting,
 - Rapid weight loss.
- Gout
- Lesch nyhan syndrome.
- Type 2 DM.
- Metabolic syndrome.

Causes of decreased levels

- Low Zinc Intake
- OCP's
- Multiple Sclerosis

Nutritional tips to manage increased Uric acid levels

- Drink plenty of fluids
- Limit animal proteins
- High Fibre foods
- Vit C Intake
- Antioxidant rich foods

TOTAL PROTEIN, SERUM-

Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum..Protein in the plasma is made up of albumin and globulin

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease
 Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-

Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

ELECTROLYTES (NA/K/CL), SERUM-

Sodium levels are Increased in dehydration, cushing's syndrome, aldosteronism & decreased in Addison's disease, hypopituitarism, liver disease. Hypokalemia (low K) is common in vomiting, diarrhea, alcoholism, folic acid deficiency and primary aldosteronism. Hyperkalemia may be seen in end-stage renal failure, hemolysis, trauma, Addison's disease, metabolic acidosis, acute starvation, dehydration, and with rapid K infusion. Chloride is increased in dehydration, renal tubular acidosis (hyperchloremia metabolic acidosis), acute renal failure, metabolic acidosis associated with prolonged diarrhea and loss of sodium bicarbonate, diabetes insipidus, adrenocortical hyperfunction, salicylate intoxication and with excessive infusion of isotonic saline or extremely high dietary intake of salt. Chloride is decreased in overhydration, chronic respiratory acidosis, salt-losing nephritis, metabolic alkalosis, congestive heart failure, Addisonian crisis, certain types of metabolic acidosis, persistent gastric secretion and prolonged vomiting.

MICROSCOPIC EXAMINATION, URINE-

Routine urine analysis assists in screening and diagnosis of various metabolic, urological, kidney and liver disorders
 Protein: Elevated proteins can be an early sign of kidney disease. Urinary protein excretion can also be temporarily elevated by strenuous exercise, orthostatic proteinuria, dehydration, urinary tract infections and acute illness with fever
 Glucose: Uncontrolled diabetes mellitus can lead to presence of glucose in urine. Other causes include pregnancy, hormonal disturbances, liver disease and certain medications.
 Ketones: Uncontrolled diabetes mellitus can lead to presence of ketones in urine. Ketones can also be seen in starvation, frequent vomiting, pregnancy and strenuous

SRL Ltd
 HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD,
 SECTOR 10,
 NAVI MUMBAI, 400703
 MAHARASHTRA, INDIA
 Tel : 022-39199222, 022-49723322, Fax :
 CIN - U74899PB1995PLC045956
 Email : -



Scan to View Details



Scan to View Report



PATIENT NAME : MRS. MANGAL CHANDRAKANT PATIL

PATIENT ID : **FH.4609607** CLIENT PATIENT ID :
 ACCESSION NO : **0022VI005164** AGE : 41 Years SEX : Female DATE OF BIRTH : 01/08/1981
 DRAWN : 24/09/2022 12:50 RECEIVED : 24/09/2022 12:55 REPORTED : 24/09/2022 15:15
 CLIENT NAME : **FORTIS VASHI-CHC -SPLZD** REFERRING DOCTOR : SELF

Test Report Status	Results	Biological Reference Interval
Final		

exercise.
 Blood: Occult blood can occur in urine as intact erythrocytes or haemoglobin, which can occur in various urological, nephrological and bleeding disorders.
 Leukocytes: An increase in leukocytes is an indication of inflammation in urinary tract or kidneys. Most common cause is bacterial urinary tract infection.
 Nitrite: Many bacteria give positive results when their number is high. Nitrite concentration during infection increases with length of time the urine specimen is retained in bladder prior to collection.
 pH: The kidneys play an important role in maintaining acid base balance of the body. Conditions of the body producing acidosis/ alkalosis or ingestion of certain type of food can affect the pH of urine.
 Specific gravity: Specific gravity gives an indication of how concentrated the urine is. Increased specific gravity is seen in conditions like dehydration, glycosuria and proteinuria while decreased specific gravity is seen in excessive fluid intake, renal failure and diabetes insipidus.
 Bilirubin: In certain liver diseases such as biliary obstruction or hepatitis, bilirubin gets excreted in urine.
 Urobilinogen: Positive results are seen in liver diseases like hepatitis and cirrhosis and in cases of hemolytic anemia

HAEMATOLOGY

CBC-5, EDTA WHOLE BLOOD

BLOOD COUNTS, EDTA WHOLE BLOOD		Low	High	g/dL
HEMOGLOBIN	10.4	12.0 - 15.0		g/dL
METHOD : SPECTROPHOTOMETRY				
RED BLOOD CELL COUNT	3.91	3.8 - 4.8		mil/ μ L
METHOD : ELECTRICAL IMPEDANCE				
WHITE BLOOD CELL COUNT	7.20	4.0 - 10.0		thou/ μ L
METHOD : DOUBLE HYDRODYNAMIC SEQUENTIAL SYSTEM(DHSS)CYTOMETRY				
PLATELET COUNT	340	150 - 410		thou/ μ L
METHOD : ELECTRICAL IMPEDANCE				
RBC AND PLATELET INDICES				
HEMATOCRIT	30.2	Low 36 - 46		%
METHOD : CALCULATED PARAMETER				
MEAN CORPUSCULAR VOLUME	77.2	Low 83 - 101		fL
METHOD : CALCULATED PARAMETER				
MEAN CORPUSCULAR HEMOGLOBIN	26.5	Low 27.0 - 32.0		pg
METHOD : CALCULATED PARAMETER				
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION	34.3	31.5 - 34.5		g/dL
METHOD : CALCULATED PARAMETER				
MENTZER INDEX	19.7			%
RED CELL DISTRIBUTION WIDTH	15.5	High 11.6 - 14.0		%
METHOD : CALCULATED PARAMETER				
MEAN PLATELET VOLUME	10.3	6.8 - 10.9		fL
METHOD : CALCULATED PARAMETER				
WBC DIFFERENTIAL COUNT - NLR				
NEUTROPHILS	52	40 - 80		%
METHOD : FLOW CYTOMETRY				
ABSOLUTE NEUTROPHIL COUNT	3.74	2.0 - 7.0		thou/ μ L
METHOD : CALCULATED PARAMETER				
LYMPHOCYTES	35	20 - 40		%
METHOD : FLOW CYTOMETRY				


SRL Ltd
 HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD,
 SECTOR 10,
 NAVI MUMBAI, 400703
 MAHARASHTRA, INDIA
 Tel : 022-39199222,022-49723322, Fax :
 CIN - U74899PB1995PLC045956
 Email : -



Scan to View Details



Scan to View Report



PATIENT NAME : MRS. MANGAL CHANDRAKANT PATIL

PATIENT ID : **FH.4609607**

CLIENT PATIENT ID :

ACCESSION NO : **0022VI005164**

AGE : 41 Years SEX : Female

DATE OF BIRTH : 01/08/1981

DRAWN : 24/09/2022 12:50

RECEIVED : 24/09/2022 12:55

REPORTED : 24/09/2022 15:15

CLIENT NAME : **FORTIS VASHI-CHC -SPLZD**

REFERRING DOCTOR : SELF

Test Report Status	Final	Results	Biological Reference Interval	
ABSOLUTE LYMPHOCYTE COUNT		2.52	1.0 - 3.0	thou/ μ L
METHOD : CALCULATED PARAMETER				
NEUTROPHIL LYMPHOCYTE RATIO (NLR)		1.5		
METHOD : CALCULATED PARAMETER				
EOSINOPHILS		4	1 - 6	%
METHOD : FLOW CYTOMETRY				
ABSOLUTE EOSINOPHIL COUNT		0.29	0.02 - 0.50	thou/ μ L
METHOD : CALCULATED PARAMETER				
MONOCYTES		9	2 - 10	%
METHOD : FLOW CYTOMETRY				
ABSOLUTE MONOCYTE COUNT		0.65	0.2 - 1.0	thou/ μ L
METHOD : CALCULATED PARAMETER				
BASOPHILS		00	0 - 2	%
METHOD : FLOW CYTOMETRY				
ABSOLUTE BASOPHIL COUNT		0	Low 0.02 - 0.10	thou/ μ L
METHOD : CALCULATED PARAMETER				
DIFFERENTIAL COUNT PERFORMED ON:		EDTA SMEAR		
MORPHOLOGY				
RBC			MILD HYPOCHROMASIA, MILD MICROCYTOSIS, MILD ANISOCYTOSIS	
METHOD : MICROSCOPIC EXAMINATION				
WBC			NORMAL MORPHOLOGY	
METHOD : MICROSCOPIC EXAMINATION				
PLATELETS			ADEQUATE	
METHOD : MICROSCOPIC EXAMINATION				
ERYTHRO SEDIMENTATION RATE, BLOOD				
SEDIMENTATION RATE (ESR)		34	High 0 - 20	mm at 1 hr
METHOD : WESTERGREIN METHOD				

Interpretation(s)

RBC AND PLATELET INDICES- Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT - NLR-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients ; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.)

ERYTHRO SEDIMENTATION RATE, BLOOD- Erythrocyte sedimentation rate (ESR) is a non - specific phenomena and is clinically useful in the diagnosis and monitoring of disorders associated with an increased production of acute phase reactants. The ESR is increased in pregnancy from about the 3rd month and returns to normal by the 4th week post partum. ESR is influenced by age, sex, menstrual cycle and drugs (eg. corticosteroids, contraceptives). It is especially low (0 -1mm) in polycythaemia, hypofibrinogenemia or congestive cardiac failure and when there are abnormalities of the red cells such as poikilocytosis, spherocytosis or sickle cells.

- Reference :
1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition
 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin
 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th Edition"

SRL Ltd
 HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD,
 SECTOR 10,
 NAVI MUMBAI, 400703
 MAHARASHTRA, INDIA
 Tel : 022-39199222,022-49723322, Fax :
 CIN - U74899PB1995PLC045956
 Email : -



Scan to View Details



Scan to View Report



PATIENT NAME : MRS. MANGAL CHANDRAKANT PATIL

PATIENT ID : **FH.4609607** CLIENT PATIENT ID :
 ACCESSION NO : **0022VI005164** AGE : 41 Years SEX : Female DATE OF BIRTH : 01/08/1981
 DRAWN : 24/09/2022 12:50 RECEIVED : 24/09/2022 12:55 REPORTED : 24/09/2022 15:15
 CLIENT NAME : **FORTIS VASHI-CHC -SPLZD** REFERRING DOCTOR : SELF

Test Report Status	Results	Biological Reference Interval
Final		

IMMUNOHAEMATOLOGY

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD


ABO GROUP TYPE O
 METHOD : TUBE AGGLUTINATION
 RH TYPE POSITIVE
 METHOD : TUBE AGGLUTINATION

Interpretation(s)
 ABO GROUP & RH TYPE, EDTA WHOLE BLOOD- Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.
 Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."
 The test is performed by both forward as well as reverse grouping methods.

BIO CHEMISTRY

GLUCOSE, POST-PRANDIAL, PLASMA

GLUCOSE, POST-PRANDIAL, PLASMA 94 70 - 139 mg/dL
 METHOD : HEXOKINASE



Comments

NOTE:- POST PRANDIAL PLASMA GLUCOSE VALUES TO BE CORRELATE WITH CLINICAL, DIETETIC AND THERAPEUTIC HISTORY
GLUCOSE, FASTING, PLASMA



Scan to View Details




Scan to View Report

PATIENT NAME : MRS. MANGAL CHANDRAKANT PATIL

PATIENT ID : **FH.4609607** CLIENT PATIENT ID :
 ACCESSION NO : **0022VI005164** AGE : 41 Years SEX : Female DATE OF BIRTH : 01/08/1981
 DRAWN : 24/09/2022 12:50 RECEIVED : 24/09/2022 12:55 REPORTED : 24/09/2022 15:15
 CLIENT NAME : **FORTIS VASHI-CHC -SPLZD** REFERRING DOCTOR : SELF

Test Report Status	Final	Results	Biological Reference Interval
GLUCOSE, FASTING, PLASMA		94	74 - 99 mg/dL



GLYCOSYLATED HEMOGLOBIN, EDTA WHOLE BLOOD

GLYCOSYLATED HEMOGLOBIN (HBA1C)	5.3	Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 ADA Target: 7.0 Action suggested: > 8.0	%
MEAN PLASMA GLUCOSE	105.4	< 116.0	mg/dL

METHOD : HB VARIANT (HPLC)
 METHOD : CALCULATED PARAMETER



Scan to View Details




Scan to View Report



PATIENT NAME : MRS. MANGAL CHANDRAKANT PATIL

PATIENT ID : **FH.4609607** CLIENT PATIENT ID :
 ACCESSION NO : **0022VI005164** AGE : 41 Years SEX : Female DATE OF BIRTH : 01/08/1981
 DRAWN : 24/09/2022 12:50 RECEIVED : 24/09/2022 12:55 REPORTED : 24/09/2022 15:15
 CLIENT NAME : **FORTIS VASHI-CHC -SPLZD** REFERRING DOCTOR : SELF

Test Report Status	Results	Biological Reference Interval
Final		



**CORONARY RISK PROFILE (LIPID PROFILE).
 SERUM**

CHOLESTEROL	126	< 200 Desirable 200 - 239 Borderline High >/= 240 High	mg/dL
METHOD : ENZYMATIC/COLORIMETRIC, CHOLESTEROL OXIDASE, ESTERASE, PEROXIDASE			
TRIGLYCERIDES	61	< 150 Normal 150 - 199 Borderline High 200 - 499 High >/=500 Very High	mg/dL
METHOD : ENZYMATIC ASSAY			
HDL CHOLESTEROL	36	Low < 40 Low >/=60 High	mg/dL
METHOD : DIRECT MEASURE - PEG			
DIRECT LDL CHOLESTEROL	78	< 100 Optimal 100 - 129 Near or above optimal 130 - 159 Borderline High 160 - 189 High >/= 190 Very High	mg/dL
METHOD : DIRECT MEASURE WITHOUT SAMPLE PRETREATMENT			
NON HDL CHOLESTEROL	90	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL
METHOD : CALCULATED PARAMETER			
CHOL/HDL RATIO	3.5	3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk	

SRL Ltd
 HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD,
 SECTOR 10,
 NAVI MUMBAI, 400703
 MAHARASHTRA, INDIA
 Tel : 022-39199222, 022-49723322, Fax :
 CIN - U74899PB1995PLC045956
 Email : -



Scan to View Details



Scan to View Report



PATIENT NAME : MRS. MANGAL CHANDRAKANT PATIL

PATIENT ID : **FH.4609607** CLIENT PATIENT ID :
 ACCESSION NO : **0022VI005164** AGE : 41 Years SEX : Female DATE OF BIRTH : 01/08/1981
 DRAWN : 24/09/2022 12:50 RECEIVED : 24/09/2022 12:55 REPORTED : 24/09/2022 15:15
 CLIENT NAME : **FORTIS VASHI-CHC -SPLZD** REFERRING DOCTOR : SELF

Test Report Status	Results	Biological Reference Interval
--------------------	---------	-------------------------------

METHOD : CALCULATED PARAMETER
LDL/HDL RATIO 2.2 > 11.0 High Risk
 0.5 - 3.0 Desirable/Low Risk
 3.1 - 6.0 Borderline/Moderate Risk
 >6.0 High Risk

METHOD : CALCULATED PARAMETER
VERY LOW DENSITY LIPOPROTEIN 12.2 <= 30.0 mg/dL
 METHOD : CALCULATED PARAMETER



PATIENT NAME : MRS. MANGAL CHANDRAKANT PATIL

PATIENT ID : **FH.4609607**

CLIENT PATIENT ID :

ACCESSION NO : **0022VI005164**

AGE : 41 Years SEX : Female

DATE OF BIRTH : 01/08/1981

DRAWN : 24/09/2022 12:50



RECEIVED : 24/09/2022 12:55

REPORTED : 24/09/2022 15:15

CLIENT NAME : **FORTIS VASHI-CHC -SPLZD**

REFERRING DOCTOR : SELF

Test Report Status	Results	Biological Reference Interval
Final		



LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL	0.18	Low 0.2 - 1.0	mg/dL
METHOD : JENDRASSIK AND GROFF			
BILIRUBIN, DIRECT	0.10	0.0 - 0.2	mg/dL
METHOD : JENDRASSIK AND GROFF			
BILIRUBIN, INDIRECT	0.08	0.1 - 1.0	mg/dL

SRL Ltd
 HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD,
 SECTOR 10,
 NAVI MUMBAI, 400703
 MAHARASHTRA, INDIA
 Tel : 022-39199222, 022-49723322, Fax :
 CIN - U74899PB1995PLC045956
 Email : -



Scan to View Details



Scan to View Report



PATIENT NAME : MRS. MANGAL CHANDRAKANT PATIL

PATIENT ID : **FH.4609607** CLIENT PATIENT ID :
 ACCESSION NO : **0022VI005164** AGE : 41 Years SEX : Female DATE OF BIRTH : 01/08/1981
 DRAWN : 24/09/2022 12:50 RECEIVED : 24/09/2022 12:55 REPORTED : 24/09/2022 15:15
 CLIENT NAME : **FORTIS VASHI-CHC -SPLZD** REFERRING DOCTOR : SELF

Test Report Status	Final	Results	Biological Reference Interval
METHOD : CALCULATED PARAMETER		8.2	6.4 - 8.2 g/dL
TOTAL PROTEIN			
METHOD : BIURET		3.8	3.4 - 5.0 g/dL
ALBUMIN			
METHOD : BCP DYE BINDING		4.4	High 2.0 - 4.1 g/dL
GLOBULIN			
METHOD : CALCULATED PARAMETER		0.9	Low 1.0 - 2.1 RATIO
ALBUMIN/GLOBULIN RATIO			
METHOD : CALCULATED PARAMETER		14	Low 15 - 37 U/L
ASPARTATE AMINOTRANSFERASE (AST/SGOT)			
METHOD : UV WITH P5P		15	< 34.0 U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT)			
METHOD : UV WITH P5P		94	30 - 120 U/L
ALKALINE PHOSPHATASE			
METHOD : PNPP-ANP		19	5 - 55 U/L
GAMMA GLUTAMYL TRANSFERASE (GGT)			
METHOD : GAMMA GLUTAMYL CARBOXY 4-NITROANILIDE		138	100 - 190 U/L
LACTATE DEHYDROGENASE			
METHOD : LACTATE -PYRUVATE			

Interpretation(s)
 GLUCOSE, POST-PRANDIAL, PLASMA-ADA Guidelines for 2hr post prandial glucose levels is only after ingestion of 75grams of glucose in 300 ml water, over a period of 5 minutes.

GLUCOSE, FASTING, PLASMA-ADA 2021 guidelines for adults, after 8 hrs fasting is as follows:
 Pre-diabetics: 100 - 125 mg/dL
 Diabetic: > or = 126 mg/dL
 GLYCOSYLATED HEMOGLOBIN, EDTA WHOLE BLOOD- Glycosylated hemoglobin (GHb) has been firmly established as an index of long-term blood glucose concentrations and as a measure of the risk for the development of complications in patients with diabetes mellitus. Formation of GHb is essentially irreversible, and the concentration in the blood depends on both the life span of the red blood cell (average 120 days) and the blood glucose concentration. Because the rate of formation of GHb is directly proportional to the concentration of glucose in the blood the GHb concentration represents the integrated values for glucose over the preceding 6-8 weeks. Any condition that alters the life span of the red blood cells has the potential to alter the GHb level. Samples from patients with hemolytic anemias will exhibit decreased glycosylated hemoglobin values due to the shortened life span of the red cells. Samples from patients with polycythemia or post-splenectomy may exhibit increased glycosylated hemoglobin values due to a somewhat longer life span of the red cells. Glycosylated hemoglobins results from patients with HbSS, HbCC, and HbSC and HbD must be interpreted with caution, given the pathological processes, including anemia increased red cell turnover, transfusion requirements, that adversely impact HbA1c as a marker of long-term glycemic control. In these conditions, alternative forms of testing such as glycosylated serum protein (fructosamine) should be considered. "Targets should be individualized; More or less stringent glycemic goals may be appropriate for individual patients. Goals should be individualized based on duration of diabetes, age/life expectancy, comorbid conditions, known CVD or advanced microvascular complications, hypoglycemia unawareness, and individual patient considerations."

References
 1. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, edited by Carl A Burtis, Edward R.Ashwood, David E Bruns, 4th Edition, Elsevier publication, 2006, 879-884.
 2. Forsham PH. Diabetes Mellitus: A rational plan for management. Postgrad Med 1982, 71,139-154.
 3. Mayer TK, Freedman ZR: Protein glycosylation in Diabetes Mellitus: A review of laboratory measurements and their clinical utility. Clin Chim Acta 1983, 127, 147-184.
 CORONARY RISK PROFILE (LIPID PROFILE). SERUM-Serum cholesterol is a blood test that can provide valuable information for the risk of coronary artery disease. This test can help determine your risk of the build up of plaques in your arteries that can lead to narrowed or blocked arteries throughout your body (atherosclerosis). High cholesterol levels usually don't cause any signs or symptoms, so a cholesterol test is an important tool. High cholesterol levels often are a significant risk factor for heart disease and important for diagnosis of hyperlipoproteinemia, atherosclerosis, hepatic and thyroid diseases.
 Serum Triglyceride are a type of fat in the blood. When you eat, your body converts any calories it doesn't need into triglycerides, which are stored in fat cells. High triglyceride levels are associated with several factors, including being overweight, eating too many sweets or drinking too much alcohol, smoking, being sedentary, or having diabetes with elevated blood sugar levels. Analysis has proven useful in the diagnosis and treatment of patients with diabetes mellitus, nephrosis, liver obstruction, other diseases involving lipid metabolism, and various endocrine disorders. In conjunction with high density lipoprotein and total serum cholesterol, a triglyceride determination provides valuable information for the assessment of coronary heart disease risk. It is done in fasting state.
 High-density lipoprotein (HDL) cholesterol. This is sometimes called the "good" cholesterol because it helps carry away LDL cholesterol, thus keeping arteries open and

SRL Ltd
 HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD,
 SECTOR 10,
 NAVI MUMBAI, 400703
 MAHARASHTRA, INDIA
 Tel : 022-39199222, 022-49723322, Fax :
 CIN - U74899PB1995PLC045956
 Email : -



Scan to View Details



Scan to View Report

Page 12 Of 13

 Patient Ref. No. 220000007

PATIENT NAME : MRS. MANGAL CHANDRAKANT PATIL

PATIENT ID : **FH.4609607** CLIENT PATIENT ID :
 ACCESSION NO : **0022VI005164** AGE : 41 Years SEX : Female DATE OF BIRTH : 01/08/1981
 DRAWN : 24/09/2022 12:50 RECEIVED : 24/09/2022 12:55 REPORTED : 24/09/2022 15:15
 CLIENT NAME : **FORTIS VASHI-CHC -SPLZD** REFERRING DOCTOR : SELF

Test Report Status	Final	Results	Biological Reference Interval
--------------------	-------	---------	-------------------------------

blood flowing more freely.HDL cholesterol is inversely related to the risk for cardiovascular disease. It increases following regular exercise, moderate alcohol consumption and with oral estrogen therapy. Decreased levels are associated with obesity, stress, cigarette smoking and diabetes mellitus.

SERUM LDL The small dense LDL test can be used to determine cardiovascular risk in individuals with metabolic syndrome or established/progressing coronary artery disease, individuals with triglyceride levels between 70 and 140 mg/dL, as well as individuals with a diet high in trans-fat or carbohydrates. Elevated sdLDL levels are associated with metabolic syndrome and an 'atherogenic lipoprotein profile', and are a strong, independent predictor of cardiovascular disease. Elevated levels of LDL arise from multiple sources. A major factor is sedentary lifestyle with a diet high in saturated fat. Insulin-resistance and pre-diabetes have also been implicated, as has genetic predisposition. Measurement of sdLDL allows the clinician to get a more comprehensive picture of lipid risk factors and tailor treatment accordingly. Reducing LDL levels will reduce the risk of CVD and MI.

Non HDL Cholesterol - Adult treatment panel ATP III suggested the addition of Non-HDL Cholesterol as an indicator of all atherogenic lipoproteins (mainly LDL and VLDL). NICE guidelines recommend Non-HDL Cholesterol measurement before initiating lipid lowering therapy. It has also been shown to be a better marker of risk in both primary and secondary prevention studies.

Recommendations:
 Results of Lipids should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.

NON FASTING LIPID PROFILE includes Total Cholesterol, HDL Cholesterol and calculated non-HDL Cholesterol. It does not include triglycerides and may be best used in patients for whom fasting is difficult.

LIVER FUNCTION PROFILE, SERUM-LIVER FUNCTION PROFILE


Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget's disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilson's disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

****End Of Report****

Please visit www.srlworld.com for related Test Information for this accession



Dr. Rekha Nair, MD
 Microbiologist



Dr. Akta Dubey
 Consultant Pathologist



Scan to View Details



Scan to View Report

PATIENT NAME : MRS. MANGAL CHANDRAKANT PATILPATIENT ID : **FH.4609607**

CLIENT PATIENT ID :

ACCESSION NO : **0022VI005212** AGE : 41 Years SEX : Female DATE OF BIRTH : 01/08/1981

DRAWN : RECEIVED : 24/09/2022 14:26 REPORTED : 26/09/2022 10:36

CLIENT NAME : **FORTIS VASHI-CHC -SPLZD**

REFERRING DOCTOR : SELF

Test Report Status

Final

Units

CYTOLOGY**PAPANICOLAOU SMEAR****PAPANICOLAOU SMEAR**

TEST METHOD

CONVENTIONAL GYNEC CYTOLOGY

SPECIMEN TYPE

TWO UNSTAINED CERVICAL SMEARS RECEIVED

REPORTING SYSTEM

2014 BETHESDA SYSTEM FOR REPORTING CERVICAL CYTOLOGY

SPECIMEN ADEQUACY

SMEARS STUDIED SHOW SUPERFICIAL SQUAMOUS CELLS, INTERMEDIATE SQUAMOUS CELLS, OCCASIONAL SQUAMOUS METAPLASTIC CELLS, OCCASIONAL CLUSTERS OF ENDOCERVICAL CELLS IN THE BACKGROUND OF FEW POLYMORPHS.

METHOD : MICROSCOPIC EXAMINATION

MICROSCOPY

SAMPLE NOT RECEIVED

Comments

PLEASE NOTE PAPANICOLAU SMEAR STUDY IS A SCREENING PROCEDURE FOR CERVICAL CANCER WITH INHERENT FALSE NEGATIVE RESULTS, HENCE SHOULD BE INTERPRETED WITH CAUTION.

NO CYTOLOGICAL EVIDENCE OF HPV INFECTION IN THE SMEARS STUDIED.

****End Of Report******Please visit www.srlworld.com for related Test Information for this accession**

Dr.Akta Dubey

Consultant Pathologist



Scan to View Details



Scan to View Report

MAGAL CHANDRAKANT PATIL
Female

4609607
41 Years

Rate 77 . Sinus rhythm.....normal P axis, V-rate 50- 99

PR 150
QRSD 91
QT 367
QTc 416

--AXIS--
P 41
QRS 55
T 33


HC

NSR
A

- NORMAL ECG -

Unconfirmed Diagnosis

12 Lead; Standard Placement



F 50~ 0.50-100 Hz W

PH100B CL P?

Speed: 25 mm/sec Limb: 10 mm/mV Chest: 10.0 mm/mV

Device:

Hiranandani Healthcare Pvt. Ltd.

Mini Sea Shore Road, Sector 10-A, Vashi, Navi Mumbai - 400703.

Board Line: 022 - 39199222 | Fax: 022 - 39133220

Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | vashi@fortishealthcare.com

CIN: U85100MH2005PTC 154823

GST IN : 27AABCH5894D1ZG

PAN NO : AABCH5894D



Hiranandani
HOSPITAL
(A Fortis Network Hospital)

Mangal Patil
41 Years / Female

Date : 24/09/2022
UHID : 4607607

X-RAY CHEST (PA VIEW)

Findings:

Both lung fields are clear.

The cardiac shadow appears within normal limits.

Trachea and major bronchi appears normal.

Both costophrenic angles are well maintained.

Bony thorax is unremarkable.

DR. YOGESH PATHADE
(MD Radio-diagnosis)

Hiranandani Healthcare Pvt. Ltd.

Mini Sea Shore Road, Sector 10-A, Vashi, Navi Mumbai - 400703.

Board Line: 022 - 39199222 | Fax: 022 - 39133220

Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | vashi@fortishealthcare.com

CIN: U85100MH2005PTC 154823

GST IN : 27AABCH5894D1ZG

PAN NO : AABCH5894D



Mangal Patil
41 Years / Female

Date : 24/09/2022
UHID : 4607607

USG – WHOLE ABDOMEN

LIVER is normal in size (14.3 cm) and echogenicity. No IHBR dilatation. No focal lesion is seen in liver. Portal vein appears normal in caliber.

GALL BLADDER is physiologically distended. Gall bladder reveals normal wall thickness. No evidence of calculi in gall bladder. No evidence of pericholecystic collection. **CBD** appears normal in caliber.

SPLEEN is normal in size (10.0 cm) and echogenicity.

BOTH KIDNEYS are normal in size and echogenicity. The central sinus complex is normal. No evidence of calculi/hydronephrosis.

Right kidney measures 8.3 x 4.7 cm.

Left kidney measures 9.6 x 4.3 cm.

PANCREAS is normal in size and morphology. No evidence of peripancreatic collection.

URINARY BLADDER is normal in capacity and contour. Bladder wall is normal in thickness. No evidence of intravesical calculi.

UTERUS is normal in size and echotexture.
Endometrium measures 4.3 mm in thickness.

Both ovaries are normal.

No evidence of ascites.

IMPRESSION:

- **No significant abnormality is detected.**


DR. YOGESH PATHADE
(MD Radio-diagnosis)

Hiranandani Healthcare Pvt. Ltd.

Mini Sea Shore Road, Sector 10-A, Vashi, Navi Mumbai - 400703.

Board Line: 022 - 39199222 | Fax: 022 - 39133220

Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | vashi@fortishealthcare.com

CIN: U85100MH2005PTC 154823

GST IN : 27AABCH5894D1ZG

PAN NO : AABCH5894D



Mangal Patil
Age: 41 yrs/Female

Date: 24/09/2022

BILATERAL DIGITAL X-RAY MAMMOGRAPHY

Findings:

Bilateral film screen mammography was performed in cranio-caudal and medio-lateral oblique views.

Both breasts show scattered areas of fibroglandular density.

Benign calcification is seen in both the breasts.

No evidence of any dominant mass, clusters of microcalcifications, nipple retraction, skin thickening or abnormal vascularity is seen in either breast.

No evidence of axillary lymphadenopathy.

IMPRESSION:

- Benign calcification in both the breasts. (BI-RADS category II).
- No obvious mass lesion in the breasts.

Normal-interval follow-up is recommended.

DR. YOGINI SHAH
DMRD., DNB. (Radiologist)